Uplizna (inebilizumab) reduces the number and size of subclinical lesions — those that cause no apparent symptoms — in the spinal cord of people with neuromyelitis optica spectrum disorder (NMOSD) about six months after the start of treatment. That’s according to a new analysis from the Phase…
Uplizna (inebilizumab)
Committee-based assessments are reliable for identifying disease attacks in people with neuromyelitis optica spectrum disorder (NMOSD) in the N-MOmentum clinical trial, which tested the approved therapy Uplizna (inebilizumab-cdon), a new study shows. The study, “Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by…
Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new data analysis from the Phase 2/3 N-MOmentum trial. Asymptomatic, or subclinical, lesions are those that don’t lead to…
Uplizna (inebilizumab) does not increase the risk of COVID-19 infection or reduce the levels of antibodies produced from prior childhood vaccines among people with neuromyelitis optica spectrum disorder (NMOSD). That’s according to two posterior analyses of data from the Phase 2/3 N-MOmentum clinical trial (NCT02200770) after the…
The Brazilian Health Regulatory Agency has approved Uplizna (inebilizumab-cdon) for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for antibodies against aquaporin-4 (AQP4-IgG). The Horizon Therapeutics’ therapy is the first and only man-made antibody against CD19 — a cell surface protein present…
Pillartree Limited, a new subsidiary of Amgen, has struck a deal to acquire Horizon Therapeutics, which markets Uplizna (inebilizumab-cdon) for neuromyelitis optica spectrum disorder (NMOSD). Last month, Horizon announced that it was in preliminary discussions about a potential sale to three pharmaceutical companies — Amgen,…
Among people with neuromyelitis optica spectrum disorder (NMOSD) who started treatment with Uplizna (inebilizumab-cdon) in a clinical trial, an early and strong reduction in B-cell counts was associated with a quicker decline in disease activity. This report comes from an analysis of data from the Phase 2/3…
Treatment with Uplizna (inebilizumab-cdon) can reduce levels of antibodies that drive neuromyelitis optica spectrum disorder (NMOSD), new clinical trial data show. The data also show that, among patients who aren’t on Uplizna, NMOSD attacks are often preceded by a sharp rise in levels of disease-driving antibodies and/or antibody-producing…
Uplizna (inebilizumab-cdon) was found effective both at reducing attacks and lessening disability in people with neuromyelitis optica spectrum disorder (NMOSD) living in Europe, according to data from the N-MOmentum Phase 2/3 trial. Nearly 90% of participants given Uplizna remained free from attacks six months after starting the therapy,…
Uplizna (inebilizumab-cdon) works to treat people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether such patients carry genetic variants linked to poor responses to other B-cell depleting therapies, new trial data show. An analysis of N-MOmentum Phase 2/3 data found that the approved therapy was as effective…
Recent Posts
- Clinical trial data show NMOSD treatment reduces relapses
- Living with NMOSD means learning how to combat decision fatigue
- Immunosuppressive treatment may lower DN-NMOSD relapse risk
- NMOSD has a way of opening our eyes to the little luxuries in life
- Adult brain can replace key cells lost in NMOSD, study finds